(Q33348406)
Statements
1 reference
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies (English)
1 reference
J P Braybrooke
1 reference
E Boven
1 reference
N P Bates
1 reference
R Ruijter
1 reference
N Dobbs
1 reference
P D Cheverton
1 reference
H M Pinedo
1 reference
D C Talbot
1 reference
1 reference
Identifiers
1 reference